Pembrolizumab is a humanized monoclonal antibody against programmed cell death 1 (PD-1), and blockade of the PD-1-programmed cell death ligand 1 (PD-L1) interaction has the potential to be an effective approach to tumor-specific immunotherapy [2]. This evidence concerns the gene CD274 and neoplasm.